During the past decade, Hamburg Onkologische Schwerpunktpraxis Eppendorf conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hamburg Onkologische Schwerpunktpraxis Eppendorf" are "Adenocarcinoma of the Stomach" (1 trials), "Cholangiocarcinoma" (1 trials), "Gallbladder Cancer" (1 trials), "GastroEsophageal Cancer" (1 trials) and "Hepatocellular Cancer" (1 trials). Many other conditions were trialed in "Hamburg Onkologische Schwerpunktpraxis Eppendorf" in a lesser frequency.

Most popular intervention types in "Hamburg Onkologische Schwerpunktpraxis Eppendorf" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "FLOT" (1 trials), "Ipilimumab" (1 trials), "Nivolumab" (1 trials) and "mFOLFOX" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hamburg Onkologische Schwerpunktpraxis Eppendorf" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hamburg Onkologische Schwerpunktpraxis Eppendorf". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Hamburg Onkologische Schwerpunktpraxis Eppendorf, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hamburg Onkologische Schwerpunktpraxis Eppendorf, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".